vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and GeneDx Holdings Corp. (WGS). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $121.0M, roughly 2.3× GeneDx Holdings Corp.). GeneDx Holdings Corp. runs the higher net margin — -14.6% vs -45.7%, a 31.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 26.5%). GeneDx Holdings Corp. produced more free cash flow last quarter ($-7.4M vs $-54.2M). Over the past eight quarters, GeneDx Holdings Corp.'s revenue compounded faster (39.2% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, Bi...
GH vs WGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $121.0M |
| Net Profit | $-128.5M | $-17.7M |
| Gross Margin | 64.6% | 69.6% |
| Operating Margin | -43.0% | -11.8% |
| Net Margin | -45.7% | -14.6% |
| Revenue YoY | 39.4% | 26.5% |
| Net Profit YoY | -15.8% | -424.9% |
| EPS (diluted) | $-1.01 | $-0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $121.0M | ||
| Q3 25 | $265.2M | $116.7M | ||
| Q2 25 | $232.1M | $102.7M | ||
| Q1 25 | $203.5M | $87.1M | ||
| Q4 24 | $201.8M | $95.6M | ||
| Q3 24 | $191.5M | $76.9M | ||
| Q2 24 | $177.2M | $70.5M | ||
| Q1 24 | $168.5M | $62.4M |
| Q4 25 | $-128.5M | $-17.7M | ||
| Q3 25 | $-92.7M | $-7.6M | ||
| Q2 25 | $-99.9M | $10.8M | ||
| Q1 25 | $-95.2M | $-6.5M | ||
| Q4 24 | $-111.0M | $5.4M | ||
| Q3 24 | $-107.8M | $-8.3M | ||
| Q2 24 | $-102.6M | $-29.2M | ||
| Q1 24 | $-115.0M | $-20.2M |
| Q4 25 | 64.6% | 69.6% | ||
| Q3 25 | 64.7% | 72.4% | ||
| Q2 25 | 65.0% | 69.0% | ||
| Q1 25 | 63.3% | 67.1% | ||
| Q4 24 | 61.6% | 69.2% | ||
| Q3 24 | 61.1% | 62.2% | ||
| Q2 24 | 59.1% | 60.9% | ||
| Q1 24 | 61.2% | 59.9% |
| Q4 25 | -43.0% | -11.8% | ||
| Q3 25 | -37.3% | -2.8% | ||
| Q2 25 | -45.9% | 8.7% | ||
| Q1 25 | -54.6% | -5.2% | ||
| Q4 24 | -62.4% | 9.2% | ||
| Q3 24 | -61.3% | -10.1% | ||
| Q2 24 | -56.8% | -15.0% | ||
| Q1 24 | -59.2% | -21.9% |
| Q4 25 | -45.7% | -14.6% | ||
| Q3 25 | -35.0% | -6.5% | ||
| Q2 25 | -43.0% | 10.5% | ||
| Q1 25 | -46.8% | -7.5% | ||
| Q4 24 | -55.0% | 5.7% | ||
| Q3 24 | -56.3% | -10.8% | ||
| Q2 24 | -57.9% | -41.4% | ||
| Q1 24 | -68.2% | -32.4% |
| Q4 25 | $-1.01 | $-0.59 | ||
| Q3 25 | $-0.74 | $-0.27 | ||
| Q2 25 | $-0.80 | $0.36 | ||
| Q1 25 | $-0.77 | $-0.23 | ||
| Q4 24 | $-0.90 | $0.25 | ||
| Q3 24 | $-0.88 | $-0.31 | ||
| Q2 24 | $-0.84 | $-1.10 | ||
| Q1 24 | $-0.94 | $-0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $171.3M |
| Total DebtLower is stronger | $1.5B | $54.5M |
| Stockholders' EquityBook value | $-99.3M | $308.2M |
| Total Assets | $2.0B | $523.7M |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $171.3M | ||
| Q3 25 | $580.0M | $155.1M | ||
| Q2 25 | $629.1M | $134.6M | ||
| Q1 25 | $698.6M | $159.2M | ||
| Q4 24 | $525.5M | $141.2M | ||
| Q3 24 | $585.0M | $116.5M | ||
| Q2 24 | $933.7M | $106.9M | ||
| Q1 24 | $1.0B | $112.9M |
| Q4 25 | $1.5B | $54.5M | ||
| Q3 25 | $1.1B | $54.8M | ||
| Q2 25 | $1.1B | $55.1M | ||
| Q1 25 | $1.1B | $55.5M | ||
| Q4 24 | $1.1B | $55.8M | ||
| Q3 24 | — | $56.1M | ||
| Q2 24 | — | $56.3M | ||
| Q1 24 | — | $56.3M |
| Q4 25 | $-99.3M | $308.2M | ||
| Q3 25 | $-354.5M | $292.3M | ||
| Q2 25 | $-305.5M | $277.1M | ||
| Q1 25 | $-250.8M | $257.4M | ||
| Q4 24 | $-139.6M | $245.2M | ||
| Q3 24 | $-60.1M | $204.5M | ||
| Q2 24 | $-1.6M | $194.0M | ||
| Q1 24 | $68.3M | $207.2M |
| Q4 25 | $2.0B | $523.7M | ||
| Q3 25 | $1.3B | $493.9M | ||
| Q2 25 | $1.3B | $463.9M | ||
| Q1 25 | $1.3B | $446.4M | ||
| Q4 24 | $1.5B | $419.4M | ||
| Q3 24 | $1.5B | $408.8M | ||
| Q2 24 | $1.6B | $389.1M | ||
| Q1 24 | $1.7B | $394.5M |
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 0.23× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-3.1M |
| Free Cash FlowOCF − Capex | $-54.2M | $-7.4M |
| FCF MarginFCF / Revenue | -19.3% | -6.1% |
| Capex IntensityCapex / Revenue | 9.9% | 3.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $14.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-3.1M | ||
| Q3 25 | $-35.4M | $15.8M | ||
| Q2 25 | $-60.3M | $10.4M | ||
| Q1 25 | $-62.7M | $10.2M | ||
| Q4 24 | $-64.5M | $-3.2M | ||
| Q3 24 | $-51.1M | $-4.4M | ||
| Q2 24 | $-94.0M | $-4.5M | ||
| Q1 24 | $-30.3M | $-16.4M |
| Q4 25 | $-54.2M | $-7.4M | ||
| Q3 25 | $-45.8M | $9.6M | ||
| Q2 25 | $-65.9M | $8.1M | ||
| Q1 25 | $-67.1M | $4.1M | ||
| Q4 24 | $-83.4M | $-6.2M | ||
| Q3 24 | $-55.3M | $-5.0M | ||
| Q2 24 | $-99.1M | $-5.9M | ||
| Q1 24 | $-37.2M | $-16.9M |
| Q4 25 | -19.3% | -6.1% | ||
| Q3 25 | -17.3% | 8.2% | ||
| Q2 25 | -28.4% | 7.8% | ||
| Q1 25 | -33.0% | 4.7% | ||
| Q4 24 | -41.3% | -6.5% | ||
| Q3 24 | -28.9% | -6.6% | ||
| Q2 24 | -55.9% | -8.3% | ||
| Q1 24 | -22.1% | -27.0% |
| Q4 25 | 9.9% | 3.6% | ||
| Q3 25 | 3.9% | 5.3% | ||
| Q2 25 | 2.4% | 2.3% | ||
| Q1 25 | 2.2% | 7.0% | ||
| Q4 24 | 9.4% | 3.2% | ||
| Q3 24 | 2.2% | 0.8% | ||
| Q2 24 | 2.9% | 1.9% | ||
| Q1 24 | 4.1% | 0.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.59× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
WGS
| Diagnostic Test Third Party Insurance | $101.1M | 84% |
| Diagnostic Test Institutional Customers | $15.5M | 13% |
| Other | $3.4M | 3% |
